BioVie (BIVI) to Release Earnings on Wednesday

BioVie (NASDAQ:BIVI) is expected to release its Q1 2026 results before the market opens on Wednesday, November 12th. Analysts expect BioVie to post earnings of ($0.79) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earningreport page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 4:00 PM ET.

BioVie Stock Performance

NASDAQ BIVI opened at $1.48 on Monday. The business’s fifty day moving average is $1.82 and its 200 day moving average is $5.81. BioVie has a fifty-two week low of $1.42 and a fifty-two week high of $38.50. The company has a market capitalization of $11.16 million, a PE ratio of -0.02 and a beta of 0.67.

Institutional Trading of BioVie

Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in BioVie during the 2nd quarter worth about $40,000. NewEdge Advisors LLC raised its stake in shares of BioVie by 283.7% in the first quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of BioVie in the second quarter worth about $57,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wall Street Zen raised shares of BioVie from a “sell” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioVie in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, BioVie has an average rating of “Moderate Buy”.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.